Due to the COVID-19 pandemic, the ACP office is closed to the public as our staff work remotely. Click here to see how this impacts our programs and operations.

New resource on myocarditis and pericarditis now available

July 21, 2021

A guide for pharmacists should patients develop symptoms of either condition following COVID-19 vaccination.  

A small number of cases of myocarditis (inflammation of the heart muscle) and/or pericarditis (inflammation of the lining around the heart) following immunization with COVID-19 vaccines have been reported in Canada and internationally. These cases are very rare and most reported cases to date have followed vaccination with an mRNA vaccine (Pfizer-BioNTech and Moderna) and were resolved with symptomatic therapy within days.  

As part of ongoing COVID-19 vaccine safety efforts, Alberta Health is monitoring cases of myocarditis and/or pericarditis following COVID-19 vaccine, including any long-term consequences. This includes monitoring cases in the adverse events following immunization (AEFI) surveillance system, as well as domestic and international evidence. 

Alberta Health has also developed a resource for health professionals, providing the latest evidence on myocarditis and pericarditis, including recommendations and considerations for clinical diagnosis, treatment, and consultation with Albertans. The resource reflects input Alberta Health received from cardiologists and includes a summary of information and advice from the National Advisory Committee on Immunization (NACI), the Alberta Advisory Committee on Immunization (AACI), and the Centers for Disease Control and Prevention (CDC).  


← Previous ArticleNext Article →